Onconetix Inc. (ONCO)
ONCO trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/0001213900-26-027725-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ONCO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001782107 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $815K |
| Net income | -$14.0M |
| Operating income | -$17.9M |
| Net margin | -1721.0% |
| Operating margin | -2190.0% |
| Revenue growth | -67.7% |
| Cash | $5.2M |
| Total assets | $24.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the date of the issuance of these consolidated financial statements." | 10-Q 2026-08-13 |
| Cash and burn | $5.9M cash; operating cash flow -$2.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | 394,911 (2026-08-13); 1,545,704 a year earlier; 17,988,058 three years earlier. 1y figure adjusted for splits (1-for-50 overall); 3y figure adjusted for splits (1-for-170000 overall). | Cover page 2026-08-13 |
| Reverse splits, 3 years | 5; latest 1-for-10 on 2026-11-06 | Source 2026-11-06 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | MaloneBailey, LLP, Houston, Texas, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-02-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $153K, sold $144K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
| Market cap check | The listing's market cap implies 670,000 shares at the 2026-11-13 price; the latest SEC cover count is 394,911 as of 2026-08-13, 394,911 after the 1-for-10 split since. The SEC count is the older of the two, so the listing's cap is likely the current one; shares were issued since that cover page. | Nasdaq screener and SEC cover page |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $17K | -$2.9M | -$1.9M | $5.9M | $150K | $646K | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $21K | -$4.2M | -$2.1M | $3.7M | $247K | $735K | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | $304K | $5.7M | -$3.1M | $5.2M | No debt tags | $815K | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | $304K | -$8.8M | -$3.2M | $837K | $160K | $1.2M | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $106K | -$2.4M | -$1.4M | $284K | $8.7M | $1.3M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $102K | -$8.5M | -$2.0M | $1.6M | $9.0M | $1.9M | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | $712K | -$29.4M | -$918K | $647K | $18.7M | $2.5M | 10-K 2026-03-13 |
| Q3 2024 2024-09-30 | $407K | -$3.8M | -$1.1M | $341K | $9.8M | Needs four quarters | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-09-08 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-13 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-16 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-12 |
| Latest proxy CURRENT REPORT | DEFA14A | 2026-10-23 |
Source: SEC EDGAR submissions feed, 401 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -53.8% |
| 1 month | -42.2% |
| 3 months | -63.6% |
| Year to date | -99.6% |
| 1 year | -99.7% |
| From 52-week high | -99.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PPCB | Propanc Biopharma Inc. | $1.89 | -2.62% | $2.0M |
| XRTX | XORTX Therapeutics Inc. Common Shares | $1.04 | -5.45% | $1.9M |
| CMND | Clearmind Medicine Inc. Common Shares | $4.18 | -7.67% | $2.1M |
| HCWB | HCW Biologics Inc. | $0.8000 | +3.48% | $1.8M |
| SBFM | Sunshine Biopharma Inc. | $2.60 | -3.70% | $2.1M |
| DCOY | Decoy Therapeutics Inc. | $0.9010 | -7.61% | $2.1M |
| SXTP | 60 Degrees Pharmaceuticals Inc. | $0.4938 | -4.65% | $1.7M |
| ENLV | Enlivex Ltd. | $1.12 | -5.88% | $1.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier